1. Pharmaceuticals and Drug Development

Stealth Biotherapeutics Announces FDA Acceptance of Elamipretide NDA Resubmission

NEEDHAM, Mass., Aug. 21, 2025 /PRNewswire/ — Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction…

Comments to: Stealth Biotherapeutics Announces FDA Acceptance of Elamipretide NDA Resubmission

Login

Welcome to Life Science News!

"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.